SUrgical access and Pattern of Recurrence of endometrial cancer: the SUPeR Study, a multicenter retrospective observational study

Andrea Puppo,Giuseppe Migliaretti,Fabio Landoni,Stefano Uccella,Marco Camanni,Marcello Ceccaroni,Elena M. Delpiano,Giulia Mantovani,Giovanni Roviglione,Tommaso Bianchi,Tommaso Grassi,Veronica Maggi,Simone Garzon,Liliana Galli,Valerio Calandra,Elena Olearo
DOI: https://doi.org/10.1016/j.jmig.2024.01.016
IF: 4.314
2024-02-03
Journal of Minimally Invasive Gynecology
Abstract:Objective The aim of this study was to evaluate recurrence rate and pattern in a population of apparently early-stage endometrial cancer (EC) treated with minimally invasive surgery(MIS) in five Italian centers and compare it to the "historical" populations from LAP2 and LACE trials treated by laparotomy. The secondary outcomes were to establish if, among patients treated with MIS, intermediate-high/high-risk patients presented the same recurrence pattern compared to those at low/intermediate-risk and to evaluate time to first recurrence (TTR) of the study population. Methods All patients with proven recurrence of apparently early-stage EC treated with MIS from January 2017 to June 2022 were included. The laparotomic historical cohort was obtained from LAP2 and LACE trials. Results Seventy-seven recurrences occurred on the total of 1028 patients treated with MIS for apparently early-stage EC during a median follow-up time of 36 months. The rate of recurrence in our cohort did not differ significantly from the rate of the historical cohort (7.4%vs7.9%, ODDSratio OR 0.9395, CI95%0.6901-1.2792). No significant differences were noticed for local, abdominal, nodal and multiple site recurrence patterns; distant site recurrence appeared more likely in patients from the historical cohort. Postoperative low/intermediate risk patients had a higher likelihood of local recurrence compared to intermediate-high/high risk patients. Mean TTR was 19 months. No significant difference of TTR was observed for each pattern of recurrence compared to others. Conclusion MIS appears to be safe for the treatment of early-stage EC. We did not identify any recurrence pattern specifically associated with MIS in early-stage EC.
obstetrics & gynecology
What problem does this paper attempt to address?